FDA grants pozelimab-bbfg approval as the first treatment for adults and children with CHAPLE disease.

Published Date: 24 Aug 2023

A phase 2/3 trial that examined the safety and effectiveness of pozelimab-bbfg claims that all 10 patients normalized their serum albumin and IgG concentrations by week 12 according to Regeneron. The 72 weeks saw no change in these concentrations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

3.

Research finds stark disparities in treatment and survival time for people with pancreatic cancer

4.

Tumor characteristics found to differ for melanomas in children, teens and young adults

5.

Relationship-building key to addressing oncologist shortages in rural care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot